Effectiveness of Nasal Budesonide on Control of Airway Inflammation by Determining FeNO in Children With Allergic Rhinitis.
Overview
- Phase
- Phase 4
- Intervention
- Budesonide nasal spray (100 mcg bid)
- Conditions
- Allergic Rhinitis
- Sponsor
- Istituto per la Ricerca e l'Innovazione Biomedica
- Enrollment
- 39
- Locations
- 1
- Primary Endpoint
- Nasal nitric oxide (nFeNO)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
In clinical trials for treatment of allergic rhinitis a significant reduction of the total symptom score compared to baseline has been demonstrated by using nasal budesonide.Previous results in adults show that the assessment and monitoring del nasal fractional exhaled nitric oxide (nFeNO) is useful in controlling inflammation of nasal allergic rhinitis.
Primary objective of this study is to evaluate efficacy of nasal budesonide (aqueous solution) on the nasal inflammation marker (nFeNO).
Secondary outcomes are the evaluation of: changes in total nasal symptom score (Total Symptom Score, T5SS), changes in cell counts in nasal lavage (LN) and the changes reported sleep quality (Pittsburgh Sleep Quality Index, PSQI).
Investigators
Stefania La Grutta, MD
Senior Researcher
Istituto per la Ricerca e l'Innovazione Biomedica
Eligibility Criteria
Inclusion Criteria
- •history of allergic rhinitis for at least 1 year
- •children aged 6 - 14 years
- •Total Symptom Score (T5SS) more than 6 in the last 4 days before the screening visit
Exclusion Criteria
- •signs of acute respiratory infection
- •systemic immunological and metabolic disease
- •major malformations of the upper airways
- •topical or systemic therapy with antibiotics, antihistamines and corticosteroids in the 30 days prior to the study
- •patient active smoker
Arms & Interventions
Budesonide nasal (100 mcg bid)
The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
Intervention: Budesonide nasal spray (100 mcg bid)
Budesonide nasal (50 mcg bid)
The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
Intervention: Budesonide nasal spray (50 mcg bid
Outcomes
Primary Outcomes
Nasal nitric oxide (nFeNO)
Time Frame: 21 days
Assessment of the influence of nasal Budesonide (aqueous solution) on nasal FeNo (nFeNO) in children with allergic rhinitis.